State Key Laboratory for Animal Disease Control and Prevention, CollegeofVeterinaryMedicine, Lanzhou UniversityLanzhou Veterinary Research InstituteChinese Academy of Agricultural Sciences, Lanzhou, 730000, China.
Gembloux Agro-Biotech, University of Liege, Gembloux, Belgium.
Vet Res. 2024 Sep 30;55(1):128. doi: 10.1186/s13567-024-01383-x.
Picornaviridae are non-enveloped ssRNA viruses that cause diseases such as poliomyelitis, hand-foot-and-mouth disease (HFMD), hepatitis A, encephalitis, myocarditis, and foot-and-mouth disease (FMD). Virus-like particles (VLPs) vaccines mainly comprise particles formed through the self-assembly of viral capsid proteins (for enveloped viruses, envelope proteins are also an option). They do not contain the viral genome. On the other hand, the nanoparticles vaccine (NPs) is mainly composed of self-assembling biological proteins or nanomaterials, with viral antigens displayed on the surface. The presentation of viral antigens on these particles in a repetitive array can elicit a strong immune response in animals. VLPs and NPs can be powerful platforms for multivalent antigen presentation. This review summarises the development of virus-like particle vaccines (VLPs) and nanoparticle vaccines (NPs) against picornaviruses. By detailing the progress made in the fight against various picornaviruses such as poliovirus (PV), foot-and-mouth disease virus (FMDV), enterovirus (EV), Senecavirus A (SVA), and encephalomyocarditis virus (EMCV), we in turn highlight the significant strides made in vaccine technology. These advancements include diverse construction methods, expression systems, elicited immune responses, and the use of various adjuvants. We see promising prospects for the continued development and optimisation of VLPs and NPs vaccines. Future research should focus on enhancing these vaccines' immunogenicity, stability, and delivery methods. Moreover, expanding our understanding of the interplay between these vaccines and the immune system will be crucial. We hope these insights will inspire and guide fellow researchers in the ongoing quest to combat picornavirus infections more effectively.
小核糖核酸病毒科是一类无包膜的 ssRNA 病毒,可引起脊髓灰质炎、手足口病(HFMD)、甲型肝炎、脑炎、心肌炎和口蹄疫(FMD)等疾病。病毒样颗粒(VLPs)疫苗主要由病毒衣壳蛋白自组装形成的颗粒组成(对于包膜病毒,包膜蛋白也是一种选择)。它们不包含病毒基因组。另一方面,纳米颗粒疫苗(NPs)主要由自组装的生物蛋白或纳米材料组成,表面展示有病毒抗原。这些颗粒表面上以重复排列方式展示的病毒抗原可以在动物中引发强烈的免疫反应。VLPs 和 NPs 可以作为多价抗原呈递的强大平台。本综述总结了小核糖核酸病毒科病毒样颗粒疫苗(VLPs)和纳米颗粒疫苗(NPs)的发展。通过详细介绍针对脊髓灰质炎病毒(PV)、口蹄疫病毒(FMDV)、肠道病毒(EV)、塞内卡病毒 A(SVA)和脑心肌炎病毒(EMCV)等各种小核糖核酸病毒的研究进展,我们也强调了疫苗技术的重大进展。这些进展包括多样化的构建方法、表达系统、引发的免疫反应以及各种佐剂的使用。我们看到 VLPs 和 NPs 疫苗的持续开发和优化前景广阔。未来的研究应侧重于增强这些疫苗的免疫原性、稳定性和递送方法。此外,深入了解这些疫苗与免疫系统之间的相互作用至关重要。我们希望这些见解能激发和指导研究人员在抗击小核糖核酸病毒感染的持续努力中取得进展。